UK markets close in 2 hours 50 minutes

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.15-1.55 (-6.83%)
At close: 04:00PM EDT
Sign in to post a message.
  • S
    Sean
    Don't know about anyone else but the timeline of all of this from the Valneva side is suss:

    1. EU cancels the bulk covid vaccine deal deal but Valneva says they will talk to individual member states to organize separate deals and are proceeding with EU approval....so still hope for retail investors to get some money out of their covid vaccine plays.

    2. Only a couple weeks later, Valneva makes it public that not enough member states want to buy their covid vaccine and it looks like they will have to trash the whole program! I mean who makes that kind of info public so quickly? Share price halves as a result.

    3. Just ONE week later Pfizer announces the equity investment and shares double pre market back to where they were pre covid deal cancellation.

    Obviously Pfizer were in talks with Valneva about this equity investment for a number of months and the decision to buy was likely confirmed with Valneva weeks ago. So Valneva management almost certainly knew Pfizer were going to pull the trigger on this before they made their surprising announcement that nobody wanted to buy their vaccine (this is not something a company would normally announce so quickly without covering every possible solution open to them as they would know it would halve their value overnight).

    You don't have to be a conspiracy theorist to entertain the notion that Valneva management could have released that info earlier than usual to intentionally lower share prior to the Pfizer buy in. I guess retail gets screwed once again.
  • N
    Nerarob
    The U.S.� pharmaceutical giant will buy Valneva (ticker: VALN.France) at a price of #$%$9.49 per share, via a reserved capital increase, according to a statement.
  • D
    Dennis
    Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
    June 24, 2022

    VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe

    Saint Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

    With this approval, VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe. The marketing authorization will cover all 28 European Union Member States as well as Iceland, Liechtenstein, and Norway.
  • b
    biz
    With Pfizer now officially on board chances for their CoV vax being rolled out seem lower than ever....
  • J
    John in emerald isle
    valneva trading suspended waiting for press release
  • T
    T
    I’m not so sure this is a good investment. Sounds more like a lifeline — “Pfizer's deal gives Valneva a cash injection to take its Lyme disease candidate, VLA15, closer to market, and calls for the French company to shoulder 40% of development costs, up from 30% under a previous agreement.”
  • D
    Dennis
    Vaccine is approved in EU, Pfizer is a new partner of their Lyme Vaccine
  • D
    Dennis
    Nice update today on Valn's new partner
    Natalie Forbes, The Motley Fool
    Mon, June 27, 2022 at 7:53 AM
    In this article:

    PFE
    -2.35%
    Watchlist
    Recent Researchyahoo plus badge
    Research report available
    VALN
    -11.67%

    As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.
  • B
    Bob
    Toast!
  • A
    Användare
    Everyone who thought valnevas portfolio was 100% COVID-19 vaccine just got burned.
  • M
    Marcelino
    At this price Zack said SELL ! I said that at 16 Euros, Strong sell!
  • D
    Den
    Chikungunya is the best topic for Valneva for the coming months.
    Spreading rapidly
    No other vaccine in line
    FDA approval coming soon
  • s
    selmerstyle
    let’s talk lyme vaccine—when i fist started following this company covid wasn’t even a thing.

    how do we feel about the potential sales for that one…and anything else interesting in the pipeline (tired of the covid vaccine drama…need a new topic of conversation!)
  • m
    multibagger
    (ADIL) $1.30 --MCap $30 mil --- Blockbuster Phase 3 results imminent ( in June) = $$$$$$$$$$$$$$$$
    "Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of
    Alcohol Use Disorder; on track to report Phase 3 results in the current quarter"

    ####
  • D
    Dennis
    Taking profits.
  • C
    Crusher 4 U
    Where will we see this tomorrow ...30's?
  • C
    Crusher 4 U
    How can this still go up?...it looks like
  • K
    Kubla
    Thank god I sold my shares at $29 the a few days ago. Pfizer only bought to snuff out Valneva Covid vaccine probably. Chump change for them
  • J
    John in emerald isle
    losing the EU deal us very bad news.